These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 12661898

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Biochemical markers for assessment of bone metastases in patients with breast cancer.
    Hou MF, Tsai LY, Tsai SM, Huang CJ, Huang YS, Hsieh JS, Chan HM, Wang JY, Chuang CH, Chen FM, Huang TJ.
    Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer].
    Takeuchi S, Saitoh H.
    Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511
    [Abstract] [Full Text] [Related]

  • 8. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
    Li SF, Wang XR, Wang C, Chen Y, Ren L, Cui L, Tong ZS.
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Markers of bone resorption--measurement in serum, plasma or urine?
    Huber F, Traber L, Roth HJ, Heckel V, Schmidt-Gayk H.
    Clin Lab; 2003 Dec; 49(5-6):203-7. PubMed ID: 15285175
    [Abstract] [Full Text] [Related]

  • 11. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.
    Lüfter D, Richter A, Günther S, Flath B, Akrivakis C, Geppert R, Wernecke KD, Possinger K.
    Anticancer Res; 2000 Dec; 20(6D):5099-105. PubMed ID: 11326676
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [The biochemical markers of bone remodeling in cancer patients with skeletal involvement].
    Liubimova NV, Bronnikov IIu, Robins SP, Trapeznikova MF, Kushlinskiĭ NE.
    Vopr Onkol; 2000 Dec; 46(3):290-7. PubMed ID: 10976274
    [Abstract] [Full Text] [Related]

  • 15. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K, Nakatsuka K, Naka H, Miki T, Morii H, Nishizawa Y.
    J Bone Miner Metab; 2003 Dec; 21(4):217-24. PubMed ID: 12811626
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
    Massidda B, Ionta MT, Foddi MR, Mascia L, Bruder F, Aloi MB, Meleddu C, Giannoni MN.
    Anticancer Res; 1996 Dec; 16(4B):2221-3. PubMed ID: 8694547
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.